Scarica l'app Stockscreener
27.87
1.09%
0.30
Dopo l'orario di chiusura:
27.64
-0.23
-0.83%
Precedente Chiudi:
$27.57
Aprire:
$27.75
Volume 24 ore:
1.09M
Relative Volume:
0.62
Capitalizzazione di mercato:
$1.76B
Reddito:
$18.09M
Utile/perdita netta:
$-208.87M
Rapporto P/E:
-7.9345
EPS:
-3.5125
Flusso di cassa netto:
$-178.15M
1 W Prestazione:
+3.22%
1M Prestazione:
+3.03%
6M Prestazione:
+36.42%
1 anno Prestazione:
+81.68%
Intervallo 1D:
$27.26
$28.50
Intervallo di 1 settimana:
$25.65
$28.71
Portata 52W:
$8.73
$71.50
Uniqure Nv Stock (QURE) Company Profile
Nome
Uniqure Nv
Settore
Industria
Telefono
1-339-970-7000
Indirizzo
PAASHEUVELWEG 25A, AMSTERDAM
Compare QURE vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
QURE
Uniqure Nv
|
27.87 | 1.74B | 18.09M | -208.87M | -178.15M | -3.5125 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 112.92B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.18B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 55.57B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 37.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 32.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Uniqure Nv Stock (QURE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-11 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2026-03-09 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2026-03-09 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2026-03-03 | Downgrade | Mizuho | Outperform → Neutral |
| 2026-03-03 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2026-03-02 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2026-03-02 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2026-02-24 | Iniziato | Wolfe Research | Peer Perform |
| 2026-01-28 | Iniziato | Barclays | Equal Weight |
| 2025-11-04 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-08-14 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2025-04-01 | Ripresa | Chardan Capital Markets | Buy |
| 2024-12-10 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-02-29 | Downgrade | Goldman | Buy → Neutral |
| 2023-12-19 | Downgrade | Mizuho | Buy → Neutral |
| 2022-03-17 | Aggiornamento | UBS | Neutral → Buy |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-05-21 | Iniziato | UBS | Neutral |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-04-01 | Aggiornamento | Mizuho | Neutral → Buy |
| 2021-01-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-11-24 | Iniziato | H.C. Wainwright | Buy |
| 2020-11-11 | Iniziato | Berenberg | Buy |
| 2020-11-09 | Iniziato | Jefferies | Buy |
| 2020-11-04 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-10-23 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-08-25 | Iniziato | Raymond James | Strong Buy |
| 2020-07-31 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2020-06-25 | Downgrade | Mizuho | Buy → Neutral |
| 2020-06-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-06-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2019-12-03 | Iniziato | Cowen | Outperform |
| 2019-12-03 | Iniziato | Goldman | Buy |
| 2019-11-05 | Iniziato | Credit Suisse | Outperform |
| 2019-10-11 | Iniziato | Stifel | Buy |
| 2019-09-25 | Iniziato | Bernstein | Outperform |
| 2019-09-12 | Iniziato | Mizuho | Buy |
| 2019-07-30 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-07-08 | Reiterato | Cantor Fitzgerald | Overweight |
| 2019-04-12 | Iniziato | Piper Jaffray | Overweight |
| 2019-03-29 | Iniziato | Robert W. Baird | Outperform |
Mostra tutto
Uniqure Nv Borsa (QURE) Ultime notizie
uniQure (QURE) investors approve share plan, charter and board at 2026 AGM - Stock Titan
[144] uniQure N.V. SEC Filing - Stock Titan
Don't Ignore The Insider Selling In uniQure - simplywall.st
This Insider Has Just Sold Shares In UniQure - Moomoo
QURE Stock Just Shot Up 8%uniQure’s Much-Talked-About Huntington’s Disease Therapy Gets A UK Boost - Stocktwits
Why Did QURE Stock Almost Halve Pre-Market Today? - Stocktwits
RSU grant, options and tax sale for uniQure (NASDAQ: QURE) director - Stock Titan
uniQure (QURE) director trades shares, receives RSUs and stock options - Stock Titan
Tax-related share sale by uniQure (NASDAQ: QURE) chief customer officer - Stock Titan
uniQure (QURE) director receives RSUs, stock options and sells shares for taxes - Stock Titan
uniQure (QURE) director Leonard Post awarded RSUs, options and sells shares for taxes - Stock Titan
Director Jack Kaye at uniQure (QURE) gets RSUs and options, sells shares for taxes - Stock Titan
Equity awards and tax-driven share sale for uniQure (NASDAQ: QURE) director - Stock Titan
uniQure (NASDAQ: QURE) director awarded RSUs, sells shares for taxes - Stock Titan
What Caused uniQure's Dramatic Stock Plunge - Kavout
symbol__ Stock Quote Price and Forecast - CNN
UniQure (NASDAQ: QURE) reports 7,970 RSUs vest and 10,000-share 10b5-1 sale - Stock Titan
UniQure N.V. (QURE) files Rule 144 to sell 7,970 RSU shares on 06/11/2026 - Stock Titan
Jack Kaye sale notice at UniQure (NASDAQ: QURE) — 7,970 shares proposed - Stock Titan
QURE Shareholder Alert: Investors With Losses May Seek to Lead t - GuruFocus
Trading the Move, Not the Narrative: (QURE) Edition - Stock Traders Daily
Fiera Capital Corp Invests $18.39 Million in uniQure N.V. $QURE - MarketBeat
QURE Jumps 20% – Analysts Upgrade Stock On Huntington’s Disease Therapy Update, Retail Eyes $150 - Stocktwits
What Just Happened with uniQure's Earnings and FDA Update - Kavout
QURE Q1 2026 Earnings: Narrower-Than-Expected Loss Fails to Lift SharesWeak Earnings Momentum - newsline.com
Director Kaye trades uniQure (QURE) shares in 10b5-1 option exercise and sale - Stock Titan
Huntingtons Disease Market Size to Hit USD 6.48 Billion by 2035 - Precedence Research
Mizuho downgrades UniQure NV (QURE) - MSN
Form 144 uniQure N.V. For: 3 June By Investing.com - Investing.com South Africa
uniQure: Why A Shifting FDA Could Change Everything For AMT-130 (NASDAQ:QURE) - Seeking Alpha
Tracing UniQure's Tale Of Boom, Bust, And Rebound - RTTNews
(QURE) Volatility Zones as Tactical Triggers - Stock Traders Daily
uniQure stock surges 20% on Replimune FDA BLA news By Investing.com - Investing.com Australia
uniQure stock surges 20% on Replimune FDA BLA news - Investing.com
QURE News | UNIQURE NV (NASDAQ:QURE) - ChartMill
uniQure N.V. stock (IL0011559904): Gene therapy player navigates strategic reset and cash conservati - AD HOC NEWS
uniQure Q1 2026 Earnings: Narrower-Than-Expected Loss Amid No Revenue, Stock SlipsCapex Guidance - newsline.com
Numero AI and Royu Merge to Redefine How Finance Teams Operate - Benzinga
UniQure stock falls after FDA's notes on pre-application of AMT-130 - MSN
Considering Uniqure NV (QURE) Stock? Read the AMT-130 Message - Insider Monkey
Uniqure NV at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
uniQure N.V. (QURE) Stalls at $24.84 — Breakout or Breakdown? 2026-05-19PCR Moving Average - newsline.com
Price-Driven Insight from (QURE) for Rule-Based Strategy - Stock Traders Daily
Huntington's Disease Pipeline 2026: Therapies Under - openPR.com
UniQure NV (QURE) price target decreased by 26.57% to 37.82 - MSN
Mizuho maintains uniQure NV (QURE) outperform recommendation - MSN
QURE stock just shot up 8%uniQure’s much-talked-about Huntington’s disease therapy gets a UK boost - MSN
Uniqure Nv Azioni (QURE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.40%
0.29%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):